A central therapeutic strategy to prevent complications in patients with T2D is to reduce the activity of the pathological arm of the renin-angiotensin system (RAS), namely, levels and actions of angiotensin II (Ang-II). This evidence concerns the gene AGT and type 2 diabetes mellitus.